Skip to main content
All lobbying filings

FAMILIES USA FOUNDATION, INC.

Lobbying for FAMILIES USA FOUNDATION INC

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $9,000.00 expenses · posted Jul 30, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 3
Health Issues

S. 958/H.R. 8317Tech to Save Moms ActMomnibus H.R. 7973Momnibus Act To end preventable maternal mortality, severe maternal morbidity, and maternal health disparities in the United States, and for other purposes. HR6248Healthy Competition for Better Care Actlegislation to ban anticompetitive terms in insurer-provider contracts S. 2355Patients Deserve Price Tags ActLegislation to strengthen and codify federal hospital and insurer transparency rules to ensure the publication of prices in dollars and cents Lower Costs, More Transparency ActLegislation to strengthen and codify federal hospital and insurer transparency rules to ensure the publication of prices in dollars and cents H.Res.1268Resolution Recognizing Postpartum Awareness Week for Communities of Color"Legislation Recognizing the week of May 3, 2026, through May 9, 2026, as National Postpartum Awareness Week for Communities of Color. LIFT the BAR Act bill would restore access to critical public benefit programs for green card holders, DACA recipients, and other lawfully present immigrants

Medicare/Medicaid

MEDSAVING Medicare Act MEDMedicare Cost Cap Act MEDPay PCPs Acta bill to task the Centers for Medicare & Medicaid Services (CMS) with establishing hybrid payments to reward primary care providers who provide the best care to their patients MEDS.1105No UPCODE ActA bill to amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage. MEDS.5089/HR9832Medicare Dental Benefit ActTo amend title XVIII of the Social Security Act to provide for coverage of dental services under the Medicare program. MEDS.5091/HR9831Medicaid Dental Benefit Act A bill to amend title XIX of the Social Security Act to improve coverage of dental and oral health services for adults under Medicaid, and for other purposes. MEDS.5088/HR9833Ensuring Kids Have Access to Medically Necessary Dental Care ActTo amend title XXI of the Social Security Act to prohibit lifetime or annual limits on dental coverage under the Childrens Health Insurance Program, and to require wraparound coverage of dental services for certain children under such program. HR9397Premium Transparency ActTo amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to ensure health insurer accountability through publishing of overhead costs and claim payments, and to direct the Secretary of Health and Human Services to issue guidance on the provision of certain insurance information. HR9392Medicare Advantage Cost Transparency ActTo amend title XVIII of the Social Security Act to require the inclusion of certain information in Medicare Advantage encounter data. HR9644Medicare Advantage MLR Transparency ActTo amend title XVIII of the Social Security Act to promote transparency of Medicare Advantage plan information.

Pharmacy

S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. S.1040Drug Competition Enhancement ActTo amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S.1041Affordable Prescriptions for Patients ActTo amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1097Interagency Patent Coordination and Improvement Act of 2025To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. S.1095Stop STALLING ActTo enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. S.1096Preserve Access to Affordadable Generics and BiosimilarsTo prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products S.2276/3269ETHIC ActTo address patent thickets. S3014 Ensuring Timely Access to Generics Act of 2025To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S1954Biosimilar Red Tape Elimination ActTo improve the requirements for making a determination of interchangeability of a biological product and its reference product.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem